Key Highlights

  • CADL shares fell 34.68% pre-market today to $5.48 from a prior close of $8.39.
  • Aglatimagene BLA submission is now planned for mid-2027, pending FDA dialogue.
  • Cash and cash equivalents were $203.1 million as of September 30, 2026.
  • Cash is expected to fund operations into the second quarter of 2028.

Candel Therapeutics (NASDAQ:CADL) shares dropped sharply in pre-market today after the company reported third quarter results and said it now plans to submit its Biologics License Application (BLA) for aglatimagene besadenovec in localized prostate cancer in the middle of 2027. The stock was at $5.48, down 34.68% from the prior close of $8.39, which followed a 9.00% decline in the previous session.

The company said the timing reflects assay refinement timelines and ongoing dialogue with the FDA, and that the plan depends on the outcome of that dialogue. Market data show the submission had previously been targeted for the fourth quarter of 2026.

Candel is a Needham, Massachusetts-based clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer. Aglatimagene, an adenovirus-based therapy, is in a Phase 3 trial for localized prostate cancer.

Assay Refinement and Manufacturing Work Stand Between Candel and a BLA

The company said it continues BLA readiness work, including manufacturing and clinical modules. A process validation campaign has been executed at its contract manufacturer, and the validation batches are in testing and intended for commercial use, pending approval.

At the Society for Immunotherapy of Cancer annual meeting, Candel presented biomarker data from the Phase 2 PrTK05 trial that it said showed systemic activation of CD8 positive T cells after aglatimagene treatment. The company said the data provide mechanistic support for the effect seen in its Phase 3 prostate cancer trial.

It also reported updated Phase 1b data for linoserpaturev in recurrent high-grade glioma, with median overall survival of 12.0 months among 50 patients treated with a single administration. The company said some patients lived beyond three and four years.

Narrower Loss Than Expected and a New $50 Million Sales Agreement

Loss per share was $0.28, narrower than market estimates of about $0.35.

The company also entered a new $50 million at-the-market sale agreement with Jefferies, according to market data. Cash and cash equivalents were $203.1 million as of September 30, which the company expects to fund its current operating plan into the second quarter of 2028.

The 52-week range runs from $4.35 to $14.00. Market data cite an average research-firm price target of about $21.

A Later Filing Date Puts the Spotlight on the FDA Dialogue

The pre-market decline reflects a later filing timeline, not a regulatory decision, and the company said its mid-2027 plan still depends on its FDA dialogue. Biodistribution and shedding data from the PrTK05 trial remain on track, and validation batch testing continues. Those items, along with any use of the new sales agreement, are the points to watch before a submission.